How Much Does Mounjaro Cost in 2026? (With and Without Insurance)

Pricing Detail

What Determines the Price

Mounjaro (tirzepatide) is the dual GIP/GLP-1 agonist manufactured by Eli Lilly for type 2 diabetes. As of June 2026, its U.S. wholesale acquisition cost is approximately $1,079 per month, with retail cash typically $900–$1,200.

Four factors drive the bill: (1) the dispensing form — Lilly's LillyDirect Self Pay program offers single-dose vials at significantly lower cash prices than the KwikPen auto-injectors; (2) insurance status and formulary tier; (3) the diagnosis on the prescription, since type 2 diabetes is covered far more broadly than off-label weight loss (Zepbound is the weight-loss-indicated alternative); and (4) whether the Mounjaro Savings Card or a patient assistance program applies.

Coverage

Insurance Coverage Requirements

Commercial insurance: most plans cover Mounjaro for type 2 diabetes when prior authorization criteria are met — typically a documented diabetes diagnosis, an HbA1c above a plan-defined threshold, and prior trial or contraindication to first-line oral agents (metformin most often). Approved patients commonly pay a $25–$150 tiered copay.

Medicare Part D: covers Mounjaro for type 2 diabetes only. The 2026 Inflation Reduction Act $2,000 Part D out-of-pocket cap substantially reduces annual cost for high-utilizers. Medicare does not cover Mounjaro when prescribed solely for weight loss.

Off-label weight loss: most commercial plans deny Mounjaro when the diagnosis is obesity rather than diabetes. Patients seeking tirzepatide for weight management should pursue Zepbound, which is FDA-approved for chronic weight management and obstructive sleep apnea.

Manufacturer Programs

Manufacturer Savings Programs

Mounjaro Savings Card: for commercially insured patients with a type 2 diabetes prescription and prior authorization, the savings card can reduce out-of-pocket cost to as low as $25 per month. It does not apply to Medicare, Medicaid, TRICARE, or VA patients.

LillyDirect Self Pay vials: Eli Lilly's direct-to-patient pharmacy ships single-dose tirzepatide vials at meaningfully lower cash prices than the auto-injector pens — typically $349 for 2.5 mg and $499 for 5 mg, with higher doses priced above that. Vial pricing has changed multiple times since launch; reconfirm at order.

Patient assistance: the Lilly Cares Foundation offers needs-based assistance for uninsured patients who meet income criteria. Approval is not guaranteed and the application process takes weeks.

What to Avoid

Why Compounded Tirzepatide Is Cheaper — and Riskier

Compounded tirzepatide marketed by online clinics and med-spas at roughly $250–$450 per month is the cheapest tirzepatide on the market — and the least medical. These products are not FDA-approved.

The FDA removed tirzepatide from the drug shortage list in late 2024, sharply narrowing the legal basis for routine compounding. The agency has documented dosing errors, adverse events, and salt-form and impurity issues in compounded incretin products. What you save in dollars, you risk in product quality, dose accuracy, and the absence of physician supervision.

If brand Mounjaro is unaffordable for a diabetes indication, the better-medicine path is usually an insurance appeal, the Mounjaro Savings Card, or LillyDirect vials at the diabetes dose — not a compounded vial of unknown provenance.

Physician-Supervised Care

What a Physician-Supervised Program Includes — and What That Costs

The medication is only part of the bill. A real Mounjaro program — the kind Haute MD physicians build — also pays for the medicine around it: baseline labs, body composition, nutrition therapy, training programming, and quarterly reassessment.

• ·New-patient consult and intake: typically $300–$750 cash, often covered as an office visit by commercial insurance.
• ·Baseline lab panel (CBC, CMP, HbA1c, lipid panel, TSH, vitamin D, hormone panel where indicated): $150–$600 cash, often covered by insurance with appropriate diagnosis codes.
• ·Body-composition assessment (DEXA or clinical-grade bioimpedance): $75–$250 per scan; quarterly is standard.
• ·Nutrition therapy with a registered dietitian: $125–$300 per visit; some plans cover medical nutrition therapy for obesity or diabetes.
• ·Follow-up visits during titration (monthly for the first 4–6 months): $150–$400 each cash, or a standard copay with insurance.
• ·Bundled concierge GLP-1 programs in major markets typically run $400–$900 per month on top of the medication, including unlimited messaging, structured nutrition and training support, and quarterly labs and DEXA.

These costs separate medical weight loss from a $200/month compounded vial. A physician-led Mounjaro program is a treatment for a chronic disease — priced and structured accordingly.